Attovia Therapeutics names John Smither to board of directors

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.

Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).

Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, and of Genelux Corporation (Nasdaq: GNLX), where he chairs the Compensation Committee and sits on the Audit Committee. He previously served on the boards of eFFECTOR Therapeutics and Applied Molecular Transport. He holds a B.S. in Business Administration from California State University, Los Angeles.

Separately, Attovia announced that Yuling Luo, PhD, a co-founder and director, will step down from the board. Luo is credited as the inventor of the company's Attobody technology, which underpins Attovia's biotherapeutics platform.

You May Also Be Interested In

• CoStar Group acquires Zonda for $800M, adding new home data
• RenovoRx regains Nasdaq minimum bid price compliance
• Singularity Future Technology closes $5M registered direct offering